IsoRay

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Start Time: 16:30 January 1, 0000 5:00 PM ET Isoray, Inc. (NYSE:ISR ) Q3 2022 Earnings Conference Call May 10, 2022, 16:30 PM ET Company Participants Lori Woods - CEO Jonathan Hunt - CFO Mark Levin - IR Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

Isoray, Inc. (ISR) CEO Lori Woods on Q3 2022 Results - Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates

Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year

Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori Woods will participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17 at 1:20 p.m. ET. CEO Woods and Chief Financial Officer Jonathan Hunt will also host virtual one-on-one and group meetings with institutional investors during the conference.

Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Investigators from the University of Pittsburgh School of Medicine have published a clinical study demonstrating favorable outcomes for localized intermediate-risk prostate cancer patients treated with IsoRay Inc's (NYSE: ISR) Cesium-131 brachytherapy known as Cesium Blu.

IsoRay's Cesium-131 Radiation Therapy Shows Favorable Outcomes In Prostate Cancer

RICHLAND, Wash., March 02, 2022 (GLOBE NEWSWIRE) -- Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray's Cesium-131 brachytherapy, commercially known as Cesium Blu.

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray's Cesium-131

Isoray, Inc. (ISR) CEO Lori Woods on Q2 2022 Results - Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates

Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year

Isoray Announces Second Quarter Fiscal 2022 Financial Results

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022

Isoray, Inc. (ISR) CEO Lori Woods on Q1 2022 Results - Earnings Call Transcript

Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year

Isoray Announces First Quarter Fiscal 2022 Financial Results

Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know

Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021

RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray's Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS's highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently been available.

American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray's Cesium-131

Isoray(AMEX:ISR) stock fell by 3.68% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 21, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: Isoray Q4 Earnings

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2021 Results - Earnings Call Transcript

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates

Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results

Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know

Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021

Infinity Pharma

CASI Pharmaceuticals

PDS Biotechnology Corporation

Savara

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for IsoRay Stock (ISR)